Name: 俄羅斯的斯普特尼克五號疫苗可能在歐盟生產 (Russia's Sputnik V vaccine could be made in EU)
Uploaded: 2021-03-10T19:30:25.000Z
Duration: 1 min 10 s

進階被動語態

Russia's Sputnik V vaccine could be produced in Europe for the first time.

俄羅斯的斯普特尼克五號疫苗可能首次在歐洲生產。

That's after a commercial deal to produce it in Italy was signed by the Moscow based RDF Sovereign Wealth Fund, along with Swiss based pharmaceutical company Addie in an agreement will need approval from Italian regulators before production can be launched.

這是在總部位於莫斯科的RDF主權財富基金與瑞士的製藥公司Addie在協議中籤署了在意大利生產它的商業協議後，將需要意大利監管機構的準許才能啟動生產。

It's the latest sign that some EU companies don't want to wait for the European Medicines Agency to grant approval.

這是一些歐盟公司不想等待歐洲藥品管理局準許的最新跡象。

Scientists have said the Russian vaccine was almost 92% effective based on peer reviewed late stage trial results.

科學家表示，根據同行評審的後期試驗結果，俄羅斯疫苗的有效性幾乎達到92%。

Sputnik V has already been approved or is being assessed for approval in three EU member states Hungary, Slovakia and the Czech Republic.

斯普尼克五號已經在匈牙利、斯洛伐克和捷克共和國三個歐盟成員國獲得準許或正在評估準許。

EU officials have said Brussels could start negotiations with the vaccine maker if at least four member countries requested.

歐盟官員表示，如果至少有四個成員國提出要求，布魯塞爾可以與疫苗製造商展開談判。

The Italian Russian Chamber of Commerce said the move paved the way for the creation of the first Sputnik V production facility in Europe.

意大利俄羅斯商會表示，此舉為在歐洲建立第一個斯普特尼克五號生產設施鋪平了道路。

 But a senior Iemma official last week urged EU members to refrain from approving Sputnik V while the agency is still reviewing it. 

但一名伊瑪高級官員上週敦促歐盟成員國在該機構仍在審查時不要準許Sputnik V。